BioNet News, Events 15 Jan 2026 The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine for Vaccination of Teenagers, Adults and Pregnant Women in the European Union Supachai
BioNet News, Events 21 Nov 2025 BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine Against Pertussis Bangkok, November 21, 2025 - BioNet, a biotechnology company dedicated to innovative vaccines, announced today that the Committee for Medicinal… Supachai
BioNet News 17 Jan 2025 BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation Lyon, France & Bangkok, Thailand – January 17, 2025 – BioNet, a global leader in vaccine innovation, proudly announces its… Supachai
BioNet News 15 Jan 2025 LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition Andernach – LTS, a leading pharmaceutical technology company, and BioNet, a biotech manufacturer specializing in genetically engineered vaccines, announced today… Supachai
BioNet News 03 Jan 2025 BioNet’s Support for Local Communities BioNet recently teamed up with the Social Development and Human Security Office of Ayutthaya, and local volunteers to visit vulnerable… Supachai
BioNet News 31 Jul 2024 BioNet Recombinant Pertussis Vaccine Submitted to EMA BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) "Monovalent recombinant acellular pertussis vaccine proven to significantly boost immunity… Supachai
BioNet News 17 May 2024 First study to assess placental transfer of maternal antibodies after immunization with recombinant pertussis vaccines during pregnancy Pertussis (whooping cough), caused by Bordetella pertussis, is a highly contagious respiratory disease responsible for severe morbidity and about 4%… Supachai
BioNet News 12 Dec 2023 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Highlights • Recombinant pertussis vaccine is safe for both mother and newborn. • There is effective transplacental antibody transfer to… Supachai
BioNet News 22 Jun 2023 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women Highlights • Recombinant acellular pertussis vaccine is safe and immunogenic in pregnant women. • Vaccine formulations containing PTgen were non-inferior… Supachai
